<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Mediclinic International

    Mediclinic International

    Mediclinic International owns and operates hospitals and medical facilities. The H...

    Mediclinic International owns and operates hosp...

    Amount Raised:    $300,000,000
    Filing Type:    PU
    Citius Pharmaceuticals, Inc.

    Citius Pharmaceuticals, Inc.

    Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the deve...

    Citius Pharmaceuticals is a specialty pharmaceu...

    Filing Type:    PU
    Fulcrum Therapeutics, Inc.

    Fulcrum Therapeutics, Inc.

    We are a clinical-stage biopharmaceutical company focused on improving the lives o...

    We are a clinical-stage biopharmaceutical compa...

    Filing Type:    PU
    Mersana Therapeutics, Inc.

    Mersana Therapeutics, Inc.

    Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...

    Mersana Therapeutics is a clinical-stage biopha...

    Filing Type:    PU
    Sienna Biopharmaceuticals, Inc.

    Sienna Biopharmaceuticals, Inc.

    Sienna Biopharmaceuticals, Inc. is a clinical–stage biopharmaceutical company fo...

    Sienna Biopharmaceuticals, Inc. is a clinicalâ€...

    Filing Type:    PU
    ContraFect Corporation

    ContraFect Corporation

    ContraFect is a clinical-stage biotechnology company focused on discovering and de...

    ContraFect is a clinical-stage biotechnology co...

    Filing Type:    PU
    CytomX Therapeutics, Inc.

    CytomX Therapeutics, Inc.

    CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. ...

    CytomX Therapeutics develops Probody™ therape...

    Filing Type:    PU
    Principia Biopharma Inc.

    Principia Biopharma Inc.

    We are a late-stage biopharmaceutical company dedicated to bringing transformative...

    We are a late-stage biopharmaceutical company d...

    Filing Type:    PU
    ArQule, Inc.

    ArQule, Inc.

    ArQule is a biopharmaceutical company engaged in the research and development of t...

    ArQule is a biopharmaceutical company engaged i...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.